Elephas

📍 Madison, United States🗓 Founded 2020👥 107 employees💰 Last funded Aug 2022
Biotechnology Research🌐 elephas.com
Website LinkedIn
Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Elephas?
Elephas has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Elephas last raise funding?
The most recent investment in Elephas recorded on gritt.io was in August 2022.
When was Elephas founded?
Elephas was founded in 2020.
What industry is Elephas in?
Elephas operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Elephas based?
Elephas is headquartered in Madison, United States.